New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
|Videos|September 23, 2020
AUPN Leadership Minute Episode 1: How to Write a Trainee Recommendation Letter
Author(s)Alissa Willis, MD, Rohit Das, MD
Episode 1 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas. [WATCH TIME: 3 minutes]
Advertisement
WATCH TIME: 3 minutes
AUPN's Leadership Minute is a brief, highly focused summary of practical advice for Chairs, Program Directors and other leaders in academic neurology, available as both mini-podcasts and in short form videos.
The goal of this program is to provide relevant and useful information in a modicum of time, designed to fit seamlessly into our very busy schedules.
Writing compelling and succinct letters of recommendation for trainees
- Get to know your candidate better: meet them, they may be able to suggest important encounters or specific events for the letter, obtain CV and Statement of Purpose
- The letter should have three parts
- The first part of the paragraph should introduce yourself and describe concrete traits about the candidate (examples: honest, clinical reasoning, ethical skills, etc.)
- The second paragraph should compare the applicant to others you have evaluated in numerical terms, define performance variables (example honors) and provide a global assessment of the candidate
Advertisement
Related to this article
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.
Here's some of what is coming soon to NeurologyLive® this week.
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
2
Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis
3
Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows
4
2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS
5